Referring to orforglipron, its nonpeptide, oral GLP-1 receptor agonist being studied for the treatment of obesity and type-2 diabetes, the Lilly spokesperson said, Weve seen so far, we have a high degree of confidence on what this molecule could mean for patients. But several drugs on the Stat News tracker are once-a-week injectables with the sole exception of San Diego-based Skye Bioscience, which is developing a once a-month injectable drug
That's not therapy, that's an experiment
the progressive loss of muscle mass and strength associated with ageing, is already a recognised driver of frailty, falls risk and loss of independence in older populations.6 For a patient in their sixties or seventies using a GLP-1 medication, accelerated lean mass loss during treatment does not occur in isolation
However, human intestinal absorption, first-pass metabolism, and systemic bioavailability have not been measured
During the menopause transition, your estrogen and progesterone levels go on a wild roller-coaster ride, triggering all those fun symptoms we've been discussing
:max_bytes(150000):strip_icc()/GettyImages-1331502792-cdc8ea8d1bb3486d96111406aff3ae34.jpg)
